Ta-Chen Huang1,2, Cher-Wei Liang3, Yu-I Li3, Jhe-Cyuan Guo2,4, Chia-Chi Lin2, Ya-Jhen Chen1, Ann-Lii Cheng5,6,7,8, Chih-Hung Hsu5,6,8. 1. Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. 2. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. 3. Department of Pathology, Fu-Jen Catholic University Hospital, New Taipei City, Taiwan. 4. National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei, Taiwan. 5. Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. chihhunghsu@ntu.edu.tw. 6. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. chihhunghsu@ntu.edu.tw. 7. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. chihhunghsu@ntu.edu.tw. 8. National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei, Taiwan. chihhunghsu@ntu.edu.tw.
Abstract
PURPOSE: Programmed death-ligand 1 (PD-L1) expression may influence the prognosis of patients with localized esophageal cancer. The current study compared the prognostic value of PD-L1 expression between tumor cells and immune cells. METHODS: Archival esophageal tumor tissue samples were collected from patients who received paclitaxel and cisplatin-based neoadjuvant chemoradiotherapy (CRT) for locally advanced esophageal squamous cell carcinoma (ESCC) in three prospective phase II trials. PD-L1 expression on tumor and immune cells was examined immunohistochemically by using the SP142 antibody and scored by two independent pathologists. The association of PD-L1 expression with patient's outcomes was analyzed using a log-rank test and Cox regression multivariate analysis. RESULTS: A total of 100 patients were included. PD-L1 expression on tumor cells was positive (≥ 1%, TC-positive) in 55 patients; PD-L1 expression on immune cells was high (≥ 5%, IC-high) in 30 patients. TC-positive status was associated with poor overall survival (OS) (HR: 1.63, P = 0.035), whereas IC-high status was associated with improved OS (HR: 0.44, P = 0.0024). Multivariate analysis revealed that TC-positive, IC-high, and performance status were independent prognostic factors for progression-free survival and that IC-high and performance status were independent factors for OS. Furthermore, the combination of IC-high and TC-negative status was associated with the optimal OS, whereas that of TC-positive and IC-low status was associated with the worst OS. CONCLUSION: PD-L1 expression on tumor and immune cells may have different prognostic value for patients with locally advanced ESCC receiving neoadjuvant CRT. A combination of these two indexes may further improve the prognostic prediction.
PURPOSE: Programmed death-ligand 1 (PD-L1) expression may influence the prognosis of patients with localized esophageal cancer. The current study compared the prognostic value of PD-L1 expression between tumor cells and immune cells. METHODS: Archival esophageal tumor tissue samples were collected from patients who received paclitaxel and cisplatin-based neoadjuvant chemoradiotherapy (CRT) for locally advanced esophageal squamous cell carcinoma (ESCC) in three prospective phase II trials. PD-L1 expression on tumor and immune cells was examined immunohistochemically by using the SP142 antibody and scored by two independent pathologists. The association of PD-L1 expression with patient's outcomes was analyzed using a log-rank test and Cox regression multivariate analysis. RESULTS: A total of 100 patients were included. PD-L1 expression on tumor cells was positive (≥ 1%, TC-positive) in 55 patients; PD-L1 expression on immune cells was high (≥ 5%, IC-high) in 30 patients. TC-positive status was associated with poor overall survival (OS) (HR: 1.63, P = 0.035), whereas IC-high status was associated with improved OS (HR: 0.44, P = 0.0024). Multivariate analysis revealed that TC-positive, IC-high, and performance status were independent prognostic factors for progression-free survival and that IC-high and performance status were independent factors for OS. Furthermore, the combination of IC-high and TC-negative status was associated with the optimal OS, whereas that of TC-positive and IC-low status was associated with the worst OS. CONCLUSION: PD-L1 expression on tumor and immune cells may have different prognostic value for patients with locally advanced ESCC receiving neoadjuvant CRT. A combination of these two indexes may further improve the prognostic prediction.
Authors: Pedro N Aguiar; Ilka Lopes Santoro; Hakaru Tadokoro; Gilberto de Lima Lopes; Bruno Andraus Filardi; Pedro Oliveira; Giannis Mountzios; Ramon Andrade de Mello Journal: Immunotherapy Date: 2016 Impact factor: 4.196
Authors: Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce Journal: Cell Date: 2015-08-27 Impact factor: 41.582
Authors: Madison Black; Ivraym B Barsoum; Peter Truesdell; Tiziana Cotechini; Shannyn K Macdonald-Goodfellow; Margaret Petroff; D Robert Siemens; Madhuri Koti; Andrew W B Craig; Charles H Graham Journal: Oncotarget Date: 2016-03-01